- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04907968
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer (UPGRADE)
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- START Midwest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant must be at least 18 years of age, and female; Participant must be able to understand the study procedures and agree to participate in the study by providing informed consent
- Participants must have a histological diagnosis of metastatic or recurrent high-grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer.
- Participant has received 1 to 3 prior lines of therapy for their ovarian cancer; a non-platinum-based chemotherapy regimen is permitted provided it is not the most recent line of therapy. Participant must have platinum-sensitive recurrent disease
- Participant must have an ECOG performance status 0 or 1
- Participant must have measurable disease as per RECIST v1.1
- Tumor sample must be provided, either an archival tumor tissue block or slides or, if not available, a tumor tissue block or slides from a new tumor biopsy obtained through a low-risk, medically routine procedure.
- Participants with toxicity from prior therapy or surgical procedures must have recovered to ≤ Grade 1. Participants with alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, or adrenal insufficiency treated with ≤10 mg daily prednisone (or equivalent), after prior taxane therapy are exceptions to this criterion and may qualify for this study.
- Participants must have cardiac left ventricular ejection fraction (LVEF) ≥50% or ≥ the institution's lower limit of normal as measured by either Echo or MUGA scan
- Participants must have adequate organ function within 14 days prior to enrollment
- A female participant is eligible to participate if she is not pregnant or breastfeeding, if she is not a woman of childbearing potential (WOCBP), or if she is a WOCBP potential and using a contraceptive method that is highly effective.
Exclusion Criteria:
- Participant has known sensitivity to any of the study medications, or components thereof, or a history of drug or allergy that contraindicates their participation
- Participant is unable or unlikely to comply with dosing schedule and study evaluations.
- Participant has a prior hypersensitivity reaction to carboplatin requiring desensitization or discontinuation.
- Participant has prior platelet or neutrophil toxicity to carboplatin-containing therapy requiring dose reduction to AUC <5 mg x mL/min in the most recent regimen containing carboplatin
- Known history of CTCAE version 5.0 Grade 4 thrombocytopenia OR history of bleeding in association with any grade thrombocytopenia
- Participant has had major surgery within 28 days of starting study treatment, systemic anticancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), or recent radiation therapy with unresolved toxicity or within a time window of potential toxicity
- Participant has received prior treatment with mirvetuximab soravtansine or another ADC containing an auristatin or maytansinoid payload.
- Participant has untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis, or carcinomatous meningitis.
- Has a diagnosis of additional malignancy that required treatment within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix
- Participant is unwilling to be transfused with blood components.
- Participant is receiving concurrent anti-cancer therapy (e.g. chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy, investigational therapy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation - Module A (UPGRADE-A)
XMT-1536 (Upifitabmab Rilsodotin) + carboplatin is administered in groups of patients who will receive doses of XMT-1536 that increase over time.
|
Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study Other Names:
Other Names:
Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study Other Names:
|
Experimental: Dose Expansion - Module A (UPGRADE-A)
Once the MTD or RP2D is achieved in dose escalation, a new group of patients will receive XMT-1536 (Upifitamab Rilsodotin) at this fixed-dose + carboplatin.
|
Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study Other Names:
Other Names:
Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DES: Maximum tolerated dose (MTD) for Upifitamab Rilsodotin with carboplatin
Time Frame: Up to 24 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met
|
Determine the MTD of Upifitamab rilsodotin in combination with carboplatin by evaluating adverse events in combination with carboplatin
|
Up to 24 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met
|
EXP: Assess the feasibility of Upifitamab rilsodotin combination initiated at MTD or RP2D
Time Frame: First dose up until 30 days after study termination
|
Assess the feasibility of Upifitamab rilsodotin combination initiated at MTD or RP2D Assess the feasibility of Upifitamab rilsodotin combination initiated at MTD or RP2D, where the regimen will be considered feasible if at least 60% of participants complete at least four cycles of the carboplatin-upifitamab rilsodotin combination, allowing for standard treatment modifications, without discontinuing treatment earlier for reasons other than disease progression
|
First dose up until 30 days after study termination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DES and EXP: Time of maximum observed concentration of carboplatin
Time Frame: Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent
|
Determine the pharmacokinetics of carboplatin
|
Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent
|
DES and EXP: Anti-neoplastic effects of XMT-1536 (Upifitamab rilsodotin) in combination with carboplatin
Time Frame: Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
ORR (by RECIST 1.1)
|
Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
DES and EXP: Anti-neoplastic effects of XMT-1536 (Upifitamab rilsodotin) in combination with carboplatin
Time Frame: Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
DOR
|
Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
DES and EXP: Anti-neoplastic effects of XMT-1536 (Upifitamab rilsodotin) in combination with carboplatin
Time Frame: Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
DCR
|
Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
DES and EXP: Anti-neoplastic effects of XMT-1536 (Upifitamab rilsodotin) in combination with carboplatin
Time Frame: Every 90 days
|
OS
|
Every 90 days
|
DES and EXP: Assess the correlation of tumor expression of NaPi2b and objective tumor response
Time Frame: Every 8 weeks for the first 12 months, every 12 weeks on treatment, every 90 days for OS
|
Potential NaPi2b protein or RNA levels of NaPi2b transcript or other genes related to cancer measured in tumor samples Blood-based biomarkers, which may include serum cytokines, circulating immune cells, and circulating tumor cells
|
Every 8 weeks for the first 12 months, every 12 weeks on treatment, every 90 days for OS
|
DES and EXP: Safety and Tolerability, by observance of frequency and grade of adverse events based on CTCAE v5.0.
Time Frame: First dose up until 30 days after study termination
|
DES and EXP: Safety and Tolerability, by observance of frequency and grade of adverse events based on CTCAE v5.0.
|
First dose up until 30 days after study termination
|
DES and EXP: Maximum concentration of XMT-1536 (Upifitamab rilsodotin)
Time Frame: weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
Determine the pharmacokinetics of XMT-1536 (Upifitamab rilsodotin)
|
weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
DES and EXP: Maximum concentration of carboplatin
Time Frame: Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
Determine the pharmacokinetics of carboplatin
|
Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
DES and EXP: Area under the concentration curve of the last measurable concentration of XMT-1536 (upifitamab rilsodotin)
Time Frame: Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
Determine the pharmacokinetics of XMT-1536 (Upifitamab rilsodotin)
|
Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
DES and EXP: Area under the concentration curve of the last measurable concentration of carboplatin
Time Frame: Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
Determine the pharmacokinetics of carboplatin
|
Weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses
|
DES and EXP: Anti-neoplastic effects of XMT-1536 (Upifitamab rilsodotin) in combination with carboplatin PFS (by RECIST 1.1)
Time Frame: Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
PFS (by RECIST 1.1)
|
Every 8 weeks for the first 12 months, then every 12 weeks on treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Brad Sumrow, MD, Mersana Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Antineoplastic Agents
- Carboplatin
Other Study ID Numbers
- XMT-1536-2A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platinum-sensitive Ovarian Cancer (UPGRADE-A)
-
University of SaskatchewanSanofiTerminatedPlatinum Sensitive Relapsed Ovarian CancerCanada
-
TILT Biotherapeutics Ltd.Merck Sharp & Dohme LLCRecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditionsUnited States, Finland
-
Rhizen Pharmaceuticals SACompletedSolid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal CancerCzechia, Poland
-
Roswell Park Cancer InstituteActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
-
Zai Lab (Shanghai) Co., Ltd.Active, not recruitingPlatinum-sensitive Relapsed Ovarian CancerChina
-
Massachusetts General HospitalTerminatedRecurrent Ovarian Cancer | Platinum Sensitive Ovarian CancerUnited States
-
Marker Therapeutics, Inc.TerminatedOvarian Cancer | Platinum Sensitive Ovarian CancerUnited States
-
AstraZenecaMyriad Genetic Laboratories, Inc.WithdrawnPlatinum Sensitive Relapsed Ovarian CancerUnited States, Korea, Republic of, Peru, United Kingdom, Philippines
-
Yonsei UniversityTakedaRecruitingPlatinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorKorea, Republic of
-
AstraZenecaISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALITerminatedPatients With Advanced Ovarian Cancer Sensitive to Platinum-based ChemotherapyItaly, Germany
Clinical Trials on XMT-1536 (Upifitamab Rilsodotin)
-
Mersana TherapeuticsIQVIA Biotech; PSI CRORecruitingPlatinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer MetastaticUnited States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
-
Mersana TherapeuticsGOG Foundation; European Network of Gynaecological Oncological Trial Groups...TerminatedUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian CancerUnited States, Australia, Canada